JFG
KALV

Jefferies Financial Group’s KalVista Pharmaceuticals KALV Stock Holding History

Jefferies Financial Group’s Portfolio KALV Stock Details KALV Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q2 		– Sell
-158,300
Closed -$1.83M – 1578
2025
Q1 		$1.83M Buy
+158,300
New +$1.62M 0.02% 604

Other funds holding KALV

VA
VR Adviser New York $2.68B AUM 422.73% 1-Year Est. Return
FLSM
Frazier Life Sciences Management Palo Alto, California $3.89B AUM 201.1% 1-Year Est. Return
SCM
Suvretta Capital Management New York $3.92B AUM 86.67% 1-Year Est. Return
TCM
Tang Capital Management San Diego, California $1.97B AUM 125.1% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
SCM
Silverarc Capital Management Boston, Massachusetts $980M AUM 470.8% 1-Year Est. Return
Capital World Investors
Capital World Investors Los Angeles, California $733B AUM 35.63% 1-Year Est. Return
Point72 Asset Management
Point72 Asset Management Stamford, Connecticut $78.1B AUM 55.25% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Millennium Management
Millennium Management New York $240B AUM 35.51% 1-Year Est. Return

Jefferies Financial Group's KALV Position: Q1 2026 in Review

Jefferies Financial Group opened a new position in KalVista Pharmaceuticals (KALV) in Q1 2026: 286,046 shares worth $5.76M. The stake represents 0.04% of the portfolio and ranks #319 among its holdings. This is a return to the name: Jefferies Financial Group previously reported a position in KALV as recently as Q3 2025.

Jefferies Financial Group first reported a position in KALV in Q4 2022 and has held it in 12 quarters since. The position peaked at $13.2M in Q4 2023. 183 funds tracked by Wall St. Rank hold KALV as of Q1 2026.

  • Jefferies Financial Group held 286,046 shares of KalVista Pharmaceuticals worth $5.76M as of Q1 2026.
  • KalVista Pharmaceuticals was a new Jefferies Financial Group position in Q1 2026.
  • KalVista Pharmaceuticals made up 0.04% of Jefferies Financial Group's portfolio in Q1 2026, its #319 holding.
  • Jefferies Financial Group first reported a position in KalVista Pharmaceuticals in Q4 2022 and has held it in 12 quarters since.
  • Jefferies Financial Group's KalVista Pharmaceuticals position peaked at $13.2M in Q4 2023.
  • 183 funds tracked by Wall St. Rank held KalVista Pharmaceuticals as of Q1 2026.

Based on Jefferies Financial Group's 13F filing for Q1 2026, filed 8 May 2026.